The meta-analysis indicated that, for patients with NSCLC and high PD-L1 expression, the use of pembrolizumab combined chemotherapy as the first-line treatment may have had a better effect than that with pembrolizumab alone (ORR RRpem + chemo/pem 1.62, 95% CI 1.18–2.23 and PFS HRpem + chemo/pem 0.55, 95% CI 0.32–0.97) [23]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.